Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Morgans on the Influence of HRQOL Data on the Use of Darolutamide Plus ADT in mHSPC

July 9th 2025

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

FDA Grants Fast Track Designation to TRE-515 Plus Radioligand Therapy in PSMA+ mCRPC

July 9th 2025

TRE-515 has received FDA fast track designation in combination with radioligand therapy for PSMA-positive mCRPC.

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.

Choosing a Chemotherapy-Based Triplet Regimen in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.

EU Approval Is Sought for Niraparib/Abiraterone Acetate Dual-Action Tablet in mHSPC With HRR Gene Alterations

July 7th 2025

European approval is being sought for the combination of niraparib, abiraterone acetate, and prednisone or prednisolone for HRR-mutated mHSPC.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer

June 30th 2025

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.

Patient Fitness and the Doublet vs Triplet Debate in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.

FDA Approves Illuccix Gallium Ga-68 Gozetotide Injection for Pre-Taxane Radioligand Therapy in mCRPC

June 26th 2025

Gallium Ga-68 gozetotide injection is now indicated for use in PET imaging patient selection for radioligand therapy in the pre-taxane setting for mCRPC.

Dr Tagawa on the Evaluation of Lutetium Lu 177 Rospatamab Tetraxetan Plus SOC in mCRPC

June 23rd 2025

Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.

Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC

June 23rd 2025

Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Darolutamide Plus ADT Earns Positive Opinion for European Approval From CHMP in Metastatic Hormone-Sensitive Prostate Cancer

June 20th 2025

The European Medicines Agency’s CHMP has recommended the approval of darolutamide plus ADT in mHSPC in the European Union.

FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC

June 17th 2025

The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.

Dr McKay on Data for Olaparib Plus Radium-223 in CRPC With Bone Metastases

June 16th 2025

Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.

Darolutamide/ADT Combo Delays Pain Progression and Enhances QOL in mHSPC

June 11th 2025

Alicia Morgans, MD, MPH, discusses findings from a QOL analysis of the ARANOTE trial, which evaluated darolutamide plus ADT in patients with mHSPC.

Mayo Clinic Takes the Next Step in Making Heavy Particle Therapy Available in the Western Hemisphere for Patients with Aggressive Cancers

June 11th 2025

The Mayo Clinic's new facility will house the first carbon ion therapy program in the Western Hemisphere.

Olaparib Plus Radium-223 Doubles rPFS vs Radium-223 Alone in mCRPC

June 10th 2025

Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.